Takeaway

• In patients with clear-cell renal cell carcinoma (ccRCC), adjuvant immunotherapy with pembrolizumab postnephrectomy led to a 32% reduction in the risk of disease recurrence or death compared with placebo.
• No new safety signals were observed.
• Pembrolizumab is a potential new standard of care for patients with ccRCC in the adjuvant...